Table 3 Phase 3 trials incorporating... | American Society of Hematology

Table 3

Phase 3 trials incorporating novel agent–based maintenance following ASCT

Reference (by maintenance regimen)	No.	Initial dose	Response vs comparator	Median follow-up	EFS or PFS vs comparator	OS vs comparator
Thalidomide
34	597	400 mg	CR + VGPR: 67% vs 55%	30 mo	3-y EFS: 52% vs 36%	4-y OS: 87% vs 77%
33	668	400 mg	CR: 64% vs 43%	72 mo	Median EFS: 6.0 vs 4.1 y	8-y OS: 57% vs 44%
35	269	200 mg	CR + VGPR: 63% vs 40%	3 y	3-y PFS: 42% vs 23%	3-y OS: 86% vs 75%
36	556	50 mg	CR: 31% vs 23%	52 mo	Median PFS: 34 vs 25 mo	Median OS: 73 vs 60 mo
37	492	50 mg	NR	38 mo	Median PFS: 30 vs 23 mo	3-y OS: 75% vs 80%
38	332	200 mg	NR	4.1 y	4-y PFS: 32% vs 14%	4-y OS: 68% vs 60%
Lenalidomide
28	614	10 mg	CR + VGPR: 84% vs 76%	45 mo	Median PFS: 41 vs 23 mo	4-y OS: 73% vs 75%
39	460	10 mg	NR	34 mo	Median TTP: 46 vs 27 mo	3-y OS: 88% vs 80%
Bortezomib
22	827	1.3 mg/m²	CR + VGPR: 76% vs 56%	41 mo	Median PFS: 35 vs 28 mo	5-y OS: 61% vs 55%
41	266	1.3 mg/m²	NR	24 mo	2-y PFS: 78% vs 63% vs 49%	NR

Reference (by maintenance regimen)	No.	Initial dose	Response vs comparator	Median follow-up	EFS or PFS vs comparator	OS vs comparator
Thalidomide
34	597	400 mg	CR + VGPR: 67% vs 55%	30 mo	3-y EFS: 52% vs 36%	4-y OS: 87% vs 77%
33	668	400 mg	CR: 64% vs 43%	72 mo	Median EFS: 6.0 vs 4.1 y	8-y OS: 57% vs 44%
35	269	200 mg	CR + VGPR: 63% vs 40%	3 y	3-y PFS: 42% vs 23%	3-y OS: 86% vs 75%
36	556	50 mg	CR: 31% vs 23%	52 mo	Median PFS: 34 vs 25 mo	Median OS: 73 vs 60 mo
37	492	50 mg	NR	38 mo	Median PFS: 30 vs 23 mo	3-y OS: 75% vs 80%
38	332	200 mg	NR	4.1 y	4-y PFS: 32% vs 14%	4-y OS: 68% vs 60%
Lenalidomide
28	614	10 mg	CR + VGPR: 84% vs 76%	45 mo	Median PFS: 41 vs 23 mo	4-y OS: 73% vs 75%
39	460	10 mg	NR	34 mo	Median TTP: 46 vs 27 mo	3-y OS: 88% vs 80%
Bortezomib
22	827	1.3 mg/m²	CR + VGPR: 76% vs 56%	41 mo	Median PFS: 35 vs 28 mo	5-y OS: 61% vs 55%
41	266	1.3 mg/m²	NR	24 mo	2-y PFS: 78% vs 63% vs 49%	NR

EFS, event-free survival.